The management of patients with amyloid heart disease is complex. Loop diuretics together with aldosterone antagonists represent the basis for influencing signs of congestion. In AL amyloidosis, high-dose chemotherapy followed by autologous stem cell transplantation is generally considered to be a front-...
Certain forms of amyloidosis may respond to liver, heart and/or kidney transplant. New treatments are being investigated. If patients develop severe complications from amyloidosis, those conditions will need to be treated. For example, dialysis may be necessary if kidney failure develops, and cardiac...
If amyloidosis affects the heart, it may cause shortness of breath. This happens because amyloid deposits affect the heart's ability to fill up with blood between heartbeats, which means less blood is pumped.Cardiac amyloidosismight make it harder to take deep breaths, especially when lying flat...
Amyloidosis, disease characterized by the deposition of an abnormal protein called amyloid in the connective tissues and organs of the body that inhibits normal functioning. Amyloid is a fibrous, insoluble protein-carbohydrate complex that forms when nor
There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficacy of combination ther...
Learn more about ONPATTRO® (patisiran), an FDA-approved prescription medicine for the polyneuropathy caused by hATTR amyloidosis in adults. See Important Safety Information on risk of infusion-related reactions and low vitamin A levels.
Amyloidosis occurs when the body produces abnormal proteins that bind together to form a substance called amyloid. Amyloids can deposit in any tissue or organ, including the heart, kidneys, liver and nerves. When it occurs in the heart, it's called cardi
Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician A Supplement to the Scientific Statement from the Heart Failure Society of AmericaDOI:10.1016/j.cardfail.2024.08.046 Heart Failure in Patients with Cancer – A Patient's Perspecti...
Substantial controversies exist in the exploration of the molecular mechanism of heart failure (HF) and pose challenges to the diagnosis of HF and the discovery of specific drugs for the treatment. Recently, cardiac transthyretin (TTR) amyloidosis is becoming recognized as one of major causes of un...
Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage. Tran... IJ Ogieuhi,MA Ugiomoh,K Muzofa,... - 《Egyptian Heart Journal》 被引量: 0发表: 2024年 Faculty Opinions recommendation of Tafamidis Tre...